S-1/A: Cellectar Biosciences Files S-1/A for Public Offering to Fund Clinical Pipeline Amidst Financial Challenges

Cellectar Biosciences, a late-stage clinical biopharmaceutical company, has filed an S-1/A registration statement for a public offering of up to 755,667 Class A or Class B Units to raise approximately $5.0 million, primarily to advance its cancer drug pipeline, despite facing significant financial constraints and a recent reverse stock split.

Summary

• Cellectar Biosciences is offering up to 755,667 Class A Units (one common stock share and one common warrant) at an assumed public offering price of $7.94 per unit, or Class B Units (one pre-funded warrant and one common warrant) for certain purchasers.
• The offering also includes up to 45,340 Representative Warrants and up to 1,556,674 shares of common stock issuable upon exercise of various warrants.
• The company expects to receive net proceeds of approximately $5.0 million from this offering, which will be used for general corporate purposes, working capital, operating expenses, and to initiate a Phase 1b clinical study of CLR 125 in triple-negative breast cancer.
• Cellectar is a late-stage clinical biopharmaceutical company focused on its proprietary phospholipid ether drug conjugate (PDC) delivery platform for cancer treatment.
• The company is exploring a full range of strategic alternatives, including mergers, acquisitions, partnerships, joint ventures, and licensing arrangements, to advance its platform and radiopharmaceutical drug development pipeline.
• Key programs include CLR 125 (iodine-125 Auger-emitting, Phase 1b study in TNBC planned for H2 2025), CLR 225 (actinium-225 alpha-emitting, Phase 1 study planned for H2 2025), and iopofosine I 131 (beta-emitting iodine-131).
• Iopofosine I 131 received Breakthrough Therapy Designation from the FDA on June 4, 2025, for relapsed/refractory Waldenstrom macroglobulinemia (r/r WM).
• The CLOVER-WaM Phase 2 study of iopofosine in r/r WM met its primary endpoint with a major response rate (MRR) of 58.2% (95% CI [44.50%, 75.80%], p < 0.0001), an overall response rate (ORR) of 83.6%, and disease control in 98.2% of patients.
• Responses in the CLOVER-WaM study were durable, with median duration of response not reached after 11.4 months of follow-up, and 76% of patients remaining progression-free at a median follow-up of eight months.
• Iopofosine I 131 monotherapy achieved a 7.3% complete remission (CR) rate in the highly refractory WM population.
• Common treatment-related adverse events (TRAEs) for iopofosine included thrombocytopenia (86.2%), neutropenia (80.0%), anemia (64.6%), and fatigue (33.8%), with no treatment-related deaths reported in the CLOVER-WaM study.
• The company completed a 1-for-30 reverse stock split on June 24, 2025, reducing outstanding shares from 54,361,197 to approximately 1,812,039.
• A warrant inducement on June 5, 2025, resulted in the exercise of 8,281,322 pre-Reverse Stock Split shares at a reduced price of $0.3041 per share.
• As of March 31, 2025, the consolidated cash balance was approximately $13.9 million, which is believed to fund basic budgeted operations into the fourth quarter of 2025, excluding proceeds from this offering.

Sentiment

Score: 4

Explanation: While the clinical data for iopofosine is highly promising and the Breakthrough Therapy Designation is a significant positive, the company's severe financial constraints, explicit need for further capital beyond this offering to fund ongoing trials, and recent reverse stock split indicate a precarious financial position and high operational risk. The positive clinical developments are overshadowed by the immediate and substantial funding challenges.

Positives

• Iopofosine I 131 received Breakthrough Therapy Designation from the FDA for relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) on June 4, 2025, which may expedite its development and review.
• The CLOVER-WaM Phase 2 study of iopofosine in r/r WM demonstrated statistically significant outcomes, with a major response rate (MRR) of 58.2%, an overall response rate (ORR) of 83.6%, and disease control in 98.2% of patients.
• Iopofosine's responses in the CLOVER-WaM study were durable, with median duration of response not reached after 11.4 months of follow-up and 76% of patients remaining progression-free at a median follow-up of eight months, exceeding real-world data for less pretreated patients.
• Iopofosine achieved a 7.3% complete remission (CR) rate in a highly refractory WM population, a result not reported by other approved or late-stage treatments for secondand third-line patients.
• The safety profile of iopofosine was well tolerated, consistent with previous data, with no treatment-related deaths in the CLOVER-WaM study.
• Iopofosine has received multiple Fast Track Designations (LPL/WM, r/r MM, r/r DLBCL) and Orphan Drug Designations (LPL/WM, MM, neuroblastoma, soft tissue sarcomas) from the FDA, and ODD and PRIME designation for WM from the European Commission.
• The company's PDC platform has demonstrated the ability to deliver various payloads (cytotoxic small molecules, peptides, oligonucleotides) to tumors in preclinical models, showing activity and safety.
• The Phase 1 Investigator-initiated study of iopofosine in combination with external beam radiation in recurrent head and neck cancer showed complete remission in 64% of patients and an ORR of 73%, with observed durability of tumor control (73% overall survival and 36% progression-free survival at 12 months).

Negatives

• The net proceeds from this offering (approximately $5.0 million) are explicitly stated as insufficient to progress CLR 125 through a preliminary data readout in its Phase 1b study, requiring additional funding sooner than expected.
• The company has historically incurred substantial losses and expects to continue generating operating losses for the foreseeable future, raising substantial doubt about its ability to continue as a going concern.
• New investors in this offering will incur immediate and substantial dilution of $2.10 per share.
• The company received a Nasdaq deficiency letter on January 30, 2025, for failing to meet the minimum $1.00 bid price requirement, with a compliance deadline of July 29, 2025, despite a recent reverse stock split.
• The company identified material weaknesses in its internal control over financial reporting, which led to restatements of previously issued financial statements and delayed SEC filings.
• The company's ability to initiate the planned Phase 1b study for CLR 125 and Phase 1 study for CLR 225 is subject to obtaining additional financing.
• The FDA's preferred route for accelerated approval of iopofosine in WM is via a one-trial design randomized Phase 3 trial, which is dependent on funding, indicating a potential delay in regulatory submission.

Risks

• The net proceeds from this offering, combined with existing cash, will not be sufficient to progress CLR 125 through a Phase 1b dose finding study data readout, necessitating additional funding and potentially leading to asset sales, discontinuance of operations, wind-down, or bankruptcy.
• Management has broad discretion over the use of offering proceeds, which may not effectively improve financial condition or market value.
• If a current and effective prospectus for common stock issuable upon warrant exercise is not maintained, public holders may only be able to exercise warrants on a cashless basis, reducing potential upside.
• Investors purchasing securities in this offering will incur immediate and substantial dilution in the book value of their shares ($2.10 per share).
• Significant holders may be prohibited from exercising warrants if it results in beneficial ownership exceeding 4.99% (or 9.99%).
• The Common Warrants are speculative in nature, and there is no assurance their market value will equal or exceed the exercise price.
• The company's stock price has been and may continue to be highly volatile, and future sales of a significant number of shares could depress the market price.
• There is no public market for the Common Warrants or Pre-Funded Warrants, limiting their liquidity.
• Holders of warrants have no rights as common stockholders until they acquire common stock upon exercise.
• The company has never paid dividends and does not anticipate paying them in the future.
• Future issuance of stock awards, convertible securities, warrants, or options will further dilute existing security holders' interests.
• Failure to meet Nasdaq's continued listing requirements could result in delisting, negatively impacting stock price and ability to raise capital.
• If business plans are unsuccessful, the company may not be able to continue operations as a going concern, leading to a loss of entire investment for investors.
• The company's exploration of strategic alternatives may be unsuccessful, materially adversely affecting its financial condition and operations.
• The company relies on a collaborative outsourced business model, and disruptions with third-party collaborators may impede FDA approval and delay commercialization.
• There is no assurance of successful development and commercialization of compounds; clinical trials are lengthy, expensive, and have uncertain outcomes, with earlier results not necessarily predictive of future success.
• The company may be required to suspend or discontinue clinical studies due to unexpected side effects or safety risks.
• The biopharmaceutical industry is subject to extensive and changing regulatory obligations, including increased judicial scrutiny of agency interpretations.
• The company is exposed to product, clinical, and preclinical liability risks that could create a substantial financial burden.
• Reliance on patents and specialized regulatory designations (like orphan drug classification) may not confer marketing exclusivity or other expected commercial benefits, and the company may face intellectual property infringement litigation.
• The company relies on a small number of key personnel, and their loss or inability to hire additional qualified personnel could delay product development.
• Confidentiality agreements may not adequately prevent disclosure of trade secrets or protect intellectual property.
• Acceptance of products in the marketplace is uncertain, and failure to achieve market acceptance will prevent or delay revenue generation.
• Regulatory approval is limited to specific indications, and promoting off-label use could incur significant liability.
• Unforeseen safety issues could emerge post-approval, requiring labeling changes, use limitations, or litigation.
• The market for proposed products is rapidly changing and competitive, with new therapeutics potentially rendering the company's technologies obsolete.
• The company may be unable to establish effective sales, marketing, and distribution channels or convince physicians of product benefits.
• Inadequate reimbursement from third-party payors or additional healthcare reform measures could hinder commercial success.
• The company is subject to federal and state healthcare fraud and abuse laws, and non-compliance could result in substantial penalties.
• Computer system failures or security breaches could materially adversely affect business and operations.
• Failure to meet investor and stakeholder expectations regarding environmental, social, and corporate governance (ESG) matters may damage the company's reputation.

Future Outlook

Cellectar Biosciences plans to continue advancing its proprietary phospholipid ether drug conjugate (PDC) delivery platform and radiopharmaceutical drug development pipeline. The company intends to initiate a Phase 1b clinical study for CLR 125 in triple-negative breast cancer and a Phase 1 imaging and dose escalation safety study for CLR 225 in the second half of 2025, both contingent on obtaining additional financing. For iopofosine I 131, following Breakthrough Therapy Designation, the company is pursuing strategic options for its further development and commercialization, including identifying a strategic partner, and aims to conduct a randomized Phase 3 trial for potential accelerated and full approval in Waldenstrom macroglobulinemia, which is also dependent on funding. The company anticipates continued operating losses for the foreseeable future and will require additional capital beyond this offering to sustain operations and progress its clinical programs.

Industry Context

Cellectar Biosciences operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically focusing on cancer treatment through its novel radioconjugate phospholipid ether drug conjugate (PDC) delivery platform. This platform aims to provide targeted delivery of therapeutic payloads directly to cancer cells, differentiating it from traditional treatments and radiotherapeutics by limiting exposure to healthy cells. The company's focus on rare and refractory cancers, such as Waldenstrom macroglobulinemia, multiple myeloma, and pediatric cancers, addresses areas of significant unmet medical need. The receipt of Breakthrough Therapy Designation for iopofosine I 131 highlights the potential of its targeted approach within the oncology space, aligning with broader industry trends towards precision medicine and targeted therapies. However, the industry is characterized by extensive regulatory hurdles, high development costs, and intense competition from larger pharmaceutical and biotechnology companies with greater resources.

Comparison to Industry Standards

• The CLOVER-WaM Phase 2 study results for iopofosine I 131 in relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) demonstrated a major response rate (MRR) of 58.2% and a median duration of response (DoR) not reached with 11.4 months of follow-up, with 76% of patients remaining progression-free at a median follow-up of eight months. These outcomes significantly exceed real-world data, which typically show a 4-12% MRR and a DoR of approximately six months or less for less pretreated and non-refractory patient populations.
• Iopofosine I 131 monotherapy achieved a 7.3% complete remission (CR) rate in a highly refractory WM population, which is notable as no approved or late-stage development treatments for secondand third-line r/r WM patients have reported a CR to date.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Face immediate and substantial dilution from the current offering and potential future equity raises. Risk of significant losses or loss of entire investment due to the company's ongoing financial challenges and going concern risk. Stock price volatility and potential delisting from Nasdaq could negatively impact liquidity and value.
• **Patients**: Potential beneficiaries of new cancer treatments (iopofosine, CLR 125, CLR 225) if clinical trials are successful and products receive regulatory approval. However, development delays or safety issues could impact access to these therapies.
• **Employees**: The company's success depends on attracting and retaining highly skilled personnel. Financial instability and potential operational changes (e.g., discontinuance of operations) could impact job security and morale.
• **Creditors/Suppliers**: Exposed to risks related to the company's financial condition and ability to continue as a going concern. Reliance on third-party manufacturers and contract research organizations means their operations are tied to the company's financial health and regulatory compliance.

Next Steps

• Initiate a Phase 1b clinical study of CLR 125 in triple-negative breast cancer in the second half of 2025, subject to obtaining additional financing.
• Initiate a Phase 1 imaging and dose escalation safety study for CLR 225 in the second half of 2025, subject to obtaining additional financing.
• Pursue strategic options for the further development and commercialization of iopofosine I 131, including identifying a strategic partner with adequate resources.
• Initiate a randomized Phase 3 trial for iopofosine in Waldenstrom macroglobulinemia patients previously treated with a BTKi, assessing major response rate and progression-free survival as primary endpoints, contingent on funding.
• Actively pursue additional funding from the sale of equity and/or debt securities, strategic transactions, or other sources of capital.
• Remediate identified material weaknesses in internal control over financial reporting.
• Regain and maintain compliance with Nasdaq's continued listing requirements, specifically the $1.00 minimum closing bid price, by July 29, 2025.

Key Dates

Recommendation

Keywords

Cellectar Biosciences, CLRB, SEC filing, S-1/A, public offering, common stock, warrants, pre-funded warrants, PDC platform, radioconjugate, iopofosine I 131, CLR 125, CLR 225, Waldenstrom macroglobulinemia, multiple myeloma, triple negative breast cancer, cancer treatment, biopharmaceutical, clinical trials, FDA, Breakthrough Therapy Designation, Orphan Drug Designation, Fast Track Designation, Reverse Stock Split, capital raise, dilution, risk factors, corporate governance, financial reporting